FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021000457> ?p ?o ?g. }

• W3021000457 endingPage "260" @default.
• W3021000457 startingPage "251" @default.
• W3021000457 abstract "Abstract Background Hereditary transthyretin‐mediated (hATTR) amyloidosis is a rapidly progressive and fatal disease. Patisiran is an RNA interference therapeutic that inhibits synthesis of disease‐causing mutant and wild‐type transthyretin (TTR) protein in hATTR amyloidosis. Aim The efficacy and safety of patisiran were evaluated in the Phase 3 APOLLO study in patients with hATTR amyloidosis with polyneuropathy. Methods In total, 225 patients from 19 countries, including Japan (n = 16), received patisiran 0.3 mg/kg intravenously or placebo once every 3 weeks for 18 months. Patisiran halted or improved outcomes of polyneuropathy (measured by modified Neuropathy Impairment Score +7 [mNIS+7]) and improved quality of life (QOL) (measured by Norfolk Quality of Life‐Diabetic Neuropathy questionnaire). Present analyses assess the efficacy, safety, pharmacokinetic exposure, and pharmacodynamic effect of patisiran in the Japanese sub‐population of APOLLO. Results Consistent with the overall APOLLO population, patisiran significantly improved outcomes of polyneuropathy (mNIS+7) compared with placebo at 18 months in the APOLLO Japanese patients. Patisiran treatment also demonstrated benefit in QOL, motor strength, gait speed, nutritional status, and autonomic symptoms compared with placebo at 18 months in the Japanese sub‐population. Patisiran was generally well tolerated in Japanese patients, with most adverse events mild or moderate; safety profile was similar to the overall APOLLO population, and no deaths were observed. Patisiran pharmacokinetic exposures and TTR reduction were comparable to the overall population. Conclusions Data in the Japanese sub‐population were consistent with those from the overall APOLLO population and indicate a notable health benefit for patisiran treatment in Japanese patients with hATTR amyloidosis with polyneuropathy." @default.
• W3021000457 created "2020-05-13" @default.
• W3021000457 creator A5004837566 @default.
• W3021000457 creator A5011589086 @default.
• W3021000457 creator A5017666745 @default.
• W3021000457 creator A5028467654 @default.
• W3021000457 creator A5035395158 @default.
• W3021000457 creator A5036681718 @default.
• W3021000457 creator A5043049060 @default.
• W3021000457 creator A5045535997 @default.
• W3021000457 creator A5049147704 @default.
• W3021000457 creator A5057744038 @default.
• W3021000457 creator A5059064031 @default.
• W3021000457 creator A5060703151 @default.
• W3021000457 creator A5076067507 @default.
• W3021000457 date "2020-07-21" @default.
• W3021000457 modified "2023-10-18" @default.
• W3021000457 title "Patisiran, an RNAi therapeutic for patients with hereditary transthyretin‐mediated amyloidosis: Sub‐analysis in Japanese patients from the APOLLO study" @default.
• W3021000457 cites W1495909506 @default.
• W3021000457 cites W1585658616 @default.
• W3021000457 cites W1705652151 @default.
• W3021000457 cites W1793435044 @default.
• W3021000457 cites W1967944707 @default.
• W3021000457 cites W1986782676 @default.
• W3021000457 cites W2009082034 @default.
• W3021000457 cites W2012543439 @default.
• W3021000457 cites W2046042617 @default.
• W3021000457 cites W2054138854 @default.
• W3021000457 cites W2074628855 @default.
• W3021000457 cites W2077345981 @default.
• W3021000457 cites W2080718344 @default.
• W3021000457 cites W2095232042 @default.
• W3021000457 cites W2112724119 @default.
• W3021000457 cites W2115862827 @default.
• W3021000457 cites W2118369819 @default.
• W3021000457 cites W2135388265 @default.
• W3021000457 cites W2188931003 @default.
• W3021000457 cites W2297947990 @default.
• W3021000457 cites W2405319848 @default.
• W3021000457 cites W2551198464 @default.
• W3021000457 cites W2769939529 @default.
• W3021000457 cites W2788969046 @default.
• W3021000457 cites W2809989268 @default.
• W3021000457 cites W2810909862 @default.
• W3021000457 cites W2888036721 @default.
• W3021000457 cites W2903444830 @default.
• W3021000457 cites W2908916217 @default.
• W3021000457 cites W2914529480 @default.
• W3021000457 cites W2962709515 @default.
• W3021000457 cites W2963291169 @default.
• W3021000457 cites W592543166 @default.
• W3021000457 doi "https://doi.org/10.1111/ncn3.12396" @default.
• W3021000457 hasPublicationYear "2020" @default.
• W3021000457 type Work @default.
• W3021000457 sameAs 3021000457 @default.
• W3021000457 citedByCount "2" @default.
• W3021000457 countsByYear W30210004572022 @default.
• W3021000457 countsByYear W30210004572023 @default.
• W3021000457 crossrefType "journal-article" @default.
• W3021000457 hasAuthorship W3021000457A5004837566 @default.
• W3021000457 hasAuthorship W3021000457A5011589086 @default.
• W3021000457 hasAuthorship W3021000457A5017666745 @default.
• W3021000457 hasAuthorship W3021000457A5028467654 @default.
• W3021000457 hasAuthorship W3021000457A5035395158 @default.
• W3021000457 hasAuthorship W3021000457A5036681718 @default.
• W3021000457 hasAuthorship W3021000457A5043049060 @default.
• W3021000457 hasAuthorship W3021000457A5045535997 @default.
• W3021000457 hasAuthorship W3021000457A5049147704 @default.
• W3021000457 hasAuthorship W3021000457A5057744038 @default.
• W3021000457 hasAuthorship W3021000457A5059064031 @default.
• W3021000457 hasAuthorship W3021000457A5060703151 @default.
• W3021000457 hasAuthorship W3021000457A5076067507 @default.
• W3021000457 hasBestOaLocation W30210004571 @default.
• W3021000457 hasConcept C121157162 @default.
• W3021000457 hasConcept C126322002 @default.
• W3021000457 hasConcept C142724271 @default.
• W3021000457 hasConcept C159110408 @default.
• W3021000457 hasConcept C1862650 @default.
• W3021000457 hasConcept C197934379 @default.
• W3021000457 hasConcept C204787440 @default.
• W3021000457 hasConcept C27081682 @default.
• W3021000457 hasConcept C2775892965 @default.
• W3021000457 hasConcept C2779951007 @default.
• W3021000457 hasConcept C2779951463 @default.
• W3021000457 hasConcept C2908647359 @default.
• W3021000457 hasConcept C71924100 @default.
• W3021000457 hasConcept C99454951 @default.
• W3021000457 hasConceptScore W3021000457C121157162 @default.
• W3021000457 hasConceptScore W3021000457C126322002 @default.
• W3021000457 hasConceptScore W3021000457C142724271 @default.
• W3021000457 hasConceptScore W3021000457C159110408 @default.
• W3021000457 hasConceptScore W3021000457C1862650 @default.
• W3021000457 hasConceptScore W3021000457C197934379 @default.
• W3021000457 hasConceptScore W3021000457C204787440 @default.
• W3021000457 hasConceptScore W3021000457C27081682 @default.
• W3021000457 hasConceptScore W3021000457C2775892965 @default.
• W3021000457 hasConceptScore W3021000457C2779951007 @default.
• W3021000457 hasConceptScore W3021000457C2779951463 @default.

• next